SCHEMBL19967633

SCHEMBL19967633

Cc1nn(Cc2cccc(C(N)=O)c2)c(C)c1NC(=O)c1ccc(COc2cccnc2)cc1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 5/20 0.55
ALDH1A1 P00352 2/20 0.55
MEN1 O00255 2/20 0.55
KMT2A Q03164 2/20 0.55
LMNA P02545 2/20 0.55
HTT P42858 1/20 0.55
NPC1 O15118 4/20 0.53
RAB9A P51151 4/20 0.53
CYP1A2 P05177 2/20 0.53
CYP2C9 P11712 2/20 0.53
CYP2C19 P33261 2/20 0.53
SIRT2 Q8IXJ6 12/20 0.50
SIRT1 Q96EB6 11/20 0.50
SIRT3 Q9NTG7 11/20 0.50
CYP3A4 P08684 1/20 0.48
CYP2D6 P10635 1/20 0.48
TAAR1 Q96RJ0 1/20 0.47
PLA2G1B P04054 1/20 0.46
ATG4B Q9Y4P1 1/20 0.46
RECQL P46063 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19951289 0.92 SMN1; SMN2 (0.55) SMN1; SMN2ALDH1A1MEN1KMT2ALMNA
SCHEMBL19951253 0.91 SMN1; SMN2 (0.61) SMN1; SMN2ALDH1A1MEN1KMT2ALMNA
SCHEMBL19951356 0.83 SMN1; SMN2 (0.63) SMN1; SMN2ALDH1A1MEN1KMT2ALMNA
SCHEMBL19951194 0.82 SMN1; SMN2 (0.59) SMN1; SMN2ALDH1A1MEN1KMT2ALMNA
SCHEMBL19951281 0.82 SMN1; SMN2 (0.59) SMN1; SMN2ALDH1A1MEN1KMT2ALMNA
SCHEMBL19951301 0.82 SMN1; SMN2 (0.61) SMN1; SMN2ALDH1A1MEN1KMT2ALMNA
SCHEMBL19951326 0.82 SMN1; SMN2 (0.61) SMN1; SMN2ALDH1A1MEN1KMT2ALMNA
SCHEMBL19951340 0.82 MEN1 (0.61) SMN1; SMN2ALDH1A1MEN1KMT2ALMNA
SCHEMBL19951206 0.81 SMN1; SMN2 (0.62) SMN1; SMN2ALDH1A1MEN1KMT2ALMNA
SCHEMBL19951200 0.80 SMN1; SMN2 (0.60) SMN1; SMN2ALDH1A1MEN1KMT2ALMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10357477-B2 Anticancer compounds REGENTS OF THE UNIVERSITY OF MINNESOTA (US) 2019-07-23 US disclosed
US-20180071258-A1 ANTICANCER COMPOUNDS REGENTS OF THE UNIVERSITY OF MINNESOTA 2018-03-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180071258-A1 ANTICANCER COMPOUNDS RB1, MCL1, TP53 SMN1; SMN2 2882/4885ALDH1A1 757/4885MEN1 603/4885
US-10357477-B2 Anticancer compounds RB1, MCL1, TP53 SMN1; SMN2 2882/4885ALDH1A1 757/4885MEN1 603/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.